<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657302</url>
  </required_header>
  <id_info>
    <org_study_id>YO42610</org_study_id>
    <nct_id>NCT04657302</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase I, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Glofitamab as Single Agent Administered After a Fixed, Single Dose Pretreatment of Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics, safety, tolerability, and efficacy of&#xD;
      glofitamab as a single agent following a fixed single dose of obinutuzumab in Chinese&#xD;
      patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have&#xD;
      failed two or more lines of systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">August 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Concentration of Glofitamab</measure>
    <time_frame>At pre-defined intervals up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Exposure (AUC) of Glofitamab</measure>
    <time_frame>At pre-defined intervals up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Glofitamab</measure>
    <time_frame>At pre-defined intervals up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Glofitamab</measure>
    <time_frame>At pre-defined intervals up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of Glofitamab</measure>
    <time_frame>At pre-defined intervals up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Glofitamab</measure>
    <time_frame>At pre-defined intervals up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T1/2) of Glofitamab</measure>
    <time_frame>At pre-defined intervals up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response Rate (CRR) as Assessed by an Independent Review Committee (IRC)</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies (ADA)</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed CRR</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as Assessed by IRC</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as Assessed by Investigator</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR) as Assessed by IRC and Investigator</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Response (CR) as Assessed by IRC and Investigator</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Determined by IRC and Investigator</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Overall Response (TFOR) as Assessed by IRC and Investigator</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Complete Response (TFCR) as Assessed by IRC and Investigator</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>R/R DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.</description>
    <arm_group_label>R/R DLBCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glofitamab</intervention_name>
    <description>Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).</description>
    <arm_group_label>R/R DLBCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).</description>
    <arm_group_label>R/R DLBCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed DLBCL&#xD;
&#xD;
          -  Participants must have relapsed or failed to respond to at least two lines of prior&#xD;
             systemic therapy (including at least one prior regimen containing anthracycline, and&#xD;
             at least one containing an anti-CD20-directed therapy)&#xD;
&#xD;
          -  Participants must have measurable disease: at least one bi-dimensionally measurable&#xD;
             nodal lesion, defined as &gt; 1.5 cm in its longest dimension; or at least one&#xD;
             bi-dimensionally measurable extranodal lesion, defined as &gt; 1.0 cm in its longest&#xD;
             dimension&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 1 or 1&#xD;
&#xD;
          -  Adverse events from prior anti-cancer therapy must have resolved to Grade &lt;/=1&#xD;
&#xD;
          -  Adequate liver, hematological, and renal function&#xD;
&#xD;
          -  Negative serum pregnancy test within 7 days prior to study treatment in women of&#xD;
             childbearing potential&#xD;
&#xD;
          -  Women of childbearing potential must agree to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception as defined by the protocol, and agree&#xD;
             to refrain from donating eggs during the treatment period and for at least 18 months&#xD;
             after the final dose of obinutuzumab, 2 months after the final dose of glofitamab, and&#xD;
             3 months after the final dose of tocilizumab (if applicable)&#xD;
&#xD;
          -  Men must agree to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraception as defined by the protocol, and agree to refrain from donating sperm&#xD;
             during the treatment period and for at least 3 months after the final dose of&#xD;
             obinutuzumab, 4 months after the final dose of glofitamab, and 2 months after the&#xD;
             final dose of tocilizumab (if applicable)&#xD;
&#xD;
          -  Reside in the People's Republic of China&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Richter's transformation&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection&#xD;
             (excluding fungal infections of nail beds) at study enrollment or any major episode of&#xD;
             infection within 4 weeks prior to first study treatment&#xD;
&#xD;
          -  Suspected or latent tuberculosis&#xD;
&#xD;
          -  Positive for HIV, hepatitis C (HCV), or hepatitis B (HBV)&#xD;
&#xD;
          -  Known or suspected chronic active Epstein-Barr virus infection&#xD;
&#xD;
          -  Known or suspected history of hemaphagocytic lymphohistiocytosis (HLH)&#xD;
&#xD;
          -  Prior treatment with systemic immunotherapeutic agents&#xD;
&#xD;
          -  History of treatment-emergent immune-related adverse events associated with prior&#xD;
             immunotherapeutic agents&#xD;
&#xD;
          -  Documented refractoriness to an obinutuzumab monotherapy-containing regimen&#xD;
&#xD;
          -  Treatment with standard radiotherapy, any chemotherapeutic agent, including CAR T&#xD;
             therapy&#xD;
&#xD;
          -  Prior solid organ or allogenic stem cell transplantation&#xD;
&#xD;
          -  Autologous stem cell transplantation within 100 days prior to obinutuzumab infusion&#xD;
&#xD;
          -  Active autoimmune disease requiring treatment&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy&#xD;
             (or recombinant antibody-related fusion proteins)&#xD;
&#xD;
          -  History of confirmed progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          -  Current or past history of CNS lymphoma&#xD;
&#xD;
          -  Current or past history of central nervous system (CNS) disease, such as stroke,&#xD;
             epilepsy, CNS vasculitis, or neurodegenerative disease&#xD;
&#xD;
          -  Evidence of significant, uncontrolled concomitant diseases that could affect&#xD;
             compliance with the protocol or interpretation of results, including diabetes&#xD;
             mellitus, history of relevant pulmonary disorders, and known autoimmune diseases&#xD;
&#xD;
          -  Major surgery or significant traumatic injury &lt; 28 days prior to obinutuzumab infusion&#xD;
             (excluding biopsies) or anticipation of the need for major surgery during study&#xD;
             treatment&#xD;
&#xD;
          -  Another invasive malignancy in the last 2 years&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before obinutizumab&#xD;
             infusion, or anticipation that one will be required during the study&#xD;
&#xD;
          -  Systemic immunosuppresive medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: YO42610 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

